Acceleron Pharma, Inc. (XLRN)
| Market Cap | 7.05B |
| Revenue (ttm) | 112.94M |
| Net Income (ttm) | -178.56M |
| Shares Out | 60.58M |
| EPS (ttm) | -3.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $116.50 |
| Previous Close | $118.18 |
| Change ($) | -1.68 |
| Change (%) | -1.42% |
| Day's Open | 117.72 |
| Day's Range | 115.03 - 117.63 |
| Day's Volume | 239,129 |
| 52-Week Range | 85.58 - 146.15 |
Acceleron (XLRN) delivered earnings and revenue surprises of 7.23% and -9.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, May 6, 2021 at 5:00 p.m. EDT to discuss its first quarter 2...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
Acceleron (XLRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acceleron (XLRN) reports a wider loss in the fourth quarter of 2020 on higher costs and lower revenues.
Shares of Acceleron Pharma (NASDAQ:XLRN) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 115.91% year over year to ($0.95), which misse...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth qu...
Bristol-Myers Squibb Co (NYSE: BMY) and its collaborating partner Acceleron Pharma Inc (NASDAQ: XLRN) have announced that Health Canada has approved Reblozyl (luspatercept for injection) to treat anemia...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview during the 3...
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popula...
Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to t...
Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2020 Results - Earnings Call Transcript
Acceleron Pharma's (XLRN) CEO Habib Dable On Q3 2020 Results - Quick Version Earnings Call Transcript
Acceleron (XLRN) delivered earnings and revenue surprises of -20.00% and -17.51%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development, and commercialization of TGF-beta superfamily therapeutics to ...
Acceleron (XLRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quar...
Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction
MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for the t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
Acceleron (XLRN) reported earnings 30 days ago. What's next for the stock?
The Reblozyl launch by partner Bristol-Myers Squibb is going well.
Acceleron Pharma's (XLRN) CEO Habib Dable on Q2 2020 Results - Earnings Call Transcript
Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.
Acceleron (XLRN) delivered earnings and revenue surprises of 38.18% and 23.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc.
About XLRN
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candida... [Read more...]
| Industry Biotechnology | IPO Date Sep 19, 2013 |
| CEO Habib Dable | Employees 312 |
| Stock Exchange NASDAQ | Ticker Symbol XLRN |
Financial Performance
In 2020, XLRN's revenue was $92.52 million, an increase of 25.04% compared to the previous year's $73.99 million. Losses were -$166.03 million, 33.0% more than in 2019.
Analyst Forecasts
According to 13 analysts, the average rating for XLRN stock is "Buy." The 12-month stock price forecast is 153.69, which is an increase of 31.92% from the latest price.